Clinical efficacy and safety of paroxetine hydrochloride and sertraline hydrochloride in the treatment of post-stroke depression
10.13699/j.cnki.1001-6821.2015.10.015
- VernacularTitle:帕罗西汀和盐酸舍曲林治疗脑卒中后抑郁的临床疗效及安全性评价
- Author:
Xiao-Ming LI
1
;
Ai-Hong HU
;
Qun GU
Author Information
1. 湖州市第一人民医院药剂科
- Keywords:
post-stroke depression;
paroxetine hydrochloride;
sertraline hydrochloride;
clinical efficacy;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2015;(10):815-817
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the clinical efficacy of paroxetine hydrochloride and sertraline hydrochloride in the treatment of post -stroke depression.Methods Sixty patients diagnosed with post -strke depression were recruited in this study and randomized divided into treat-ment group ( n=28 ) and control group ( n=32 ) .Patients in the treat-ment group were given paroxetine hydrochloride 20 mg? d-1 orally and patients in the control group were given sertraline hydrochloride 50 mg? d-1 orally.The treatment lasted for 12 weeks.The Hamilton rating scale for depression ( HAMD ) , National institute of health stroke scale ( NIHSS) and barthel index ( BI) were evaluated in every two weeks after the treatment.The score of HAMD, NIHSS, BI and adverse drug reac-tions were recorded and compared between the two groups .Results The clinical efficacy were 89.29% and 93.75% in the treatment group and control group respectively , without statistical difference ( P>0.05 ) .The score of HAMD , NIHSS and BI were significantly decreased after 12 weeks treatment in both groups ( P<0.05 ).But the scores at the end of the 12 weeks were not statistically different between the two groups ( P>0.05 ) . The incidence of adverse drug reactions were 21.43% and 18.75% in the treatment group and control group respectively with no statistical difference ( P>0.05 ) .Conclusion No statistical difference in clinical efficacy and safety were found between paroxetine hydrochloride and sertraline hydrochloride in the treatment of post-stroke depression , both with low incidence of adverse drug reactions .
